Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Yubo International Biotech Limited (YBGJ : OTC)
 
 • Company Description   
MAGNA-LAB INC. is a development stage company. Co. has developed and now markets and intends to produce the MAGNA-SLn, the first of Co.'s proposed series of anatomy specific MRI (Magnetic Resonance Imaging) products which are smaller and cost less to own, install and operate than present ``whole body`` MRI systems.

Number of Employees: 18

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.07 Daily Weekly Monthly
20 Day Moving Average: 1,832 shares
Shares Outstanding: 119.82 (millions)
Market Capitalization: $8.87 (millions)
Beta: 3.99
52 Week High: $0.54
52 Week Low: $0.03
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.12% -5.78%
12 Week 72.90% 45.43%
Year To Date 113.26% 99.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Room 1102 11th Floor Building 2 No. 10 Chaoyang Park South Road Chaoyang District
-
Beijing,F4 100026
CHN
ph: 86-040-0677-6010
fax: 516-595-1159
None http://www.yubogroup.com
 
 • General Corporate Information   
Officers
Yang Wang - Chief Executive Officer and Director
Jun Wang - President and Director
Lina Liu - Chief Financial Officer; Treasurer and Director
Zhihui Bai - Director
Seymour Kessler - Director

Peer Information
Yubo International Biotech Limited (ABMD)
Yubo International Biotech Limited (DMDS)
Yubo International Biotech Limited (CPWY.)
Yubo International Biotech Limited (EQUR)
Yubo International Biotech Limited (ECIA)
Yubo International Biotech Limited (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 988366100
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/18/25
Share - Related Items
Shares Outstanding: 119.82
Most Recent Split Date: 3.00 (0.01:1)
Beta: 3.99
Market Capitalization: $8.87 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/18/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -124.79
12/31/24 - -113.75
Current Ratio
06/30/25 - -
03/31/25 - 0.14
12/31/24 - 0.14
Quick Ratio
06/30/25 - -
03/31/25 - 0.14
12/31/24 - 0.14
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -57,118.15
Book Value
06/30/25 - -
03/31/25 - -0.03
12/31/24 - -0.03
Inventory Turnover
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.01
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©